Ocugen Announces FDA Clearance for Phase 2/3 Trial of OCU410ST for Stargardt Disease

Ocugen, Inc. announced that the U.S. FDA has cleared an Investigational New Drug (IND) amendment to initiate a Phase 2/3 pivotal confirmatory clinical...
Home/KnloSights/Clinical Trial Updates/Ocugen Announces FDA Clearance for Phase 2/3 Trial of OCU410ST for Stargardt Disease